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ABSTRACT 
Cyclin D1 has been recently investigated as an important protein in DNA damage repair 
mechanisms, especially in homologous recombination-directed repair (HDR). Cyclin 
D1 is recruited to damaged foci by BRCA2 and it enhances RAD51 binding to BRCA2 
because cyclin D1 prevents BRCA2 inhibitory phosphorylation on serine 3291. 
Furthermore, cyclin D1 is essential for RAD51 gene up-regulation in case of double-
stranded break (DSB). Meanwhile molecule 3l, an E-3-(2-chloro-3-
indolylmethylene)1,3-dihydroindol-2one, has been showed to reduce cyclin D1 
transcript and protein levels and, for this reason, 3l treatment could be used to study 
cyclin D1 role in DNA damage repair, especially in ovarian cancer, that has not been 
well addressed yet. 
Scope of this thesis is to find a new possible combined approach to increase sensitivity 
of ovarian cancer IGROV1 cells to irradiation: 3l treatment for 24 hours in order to 
deplete cyclin D1 expression, with a further UV irradiation to induce DNA damages. In 
this case, the repair of induced DSBs are analyzed in cells with a small amount of cyclin 
D1. 
Time and duration of UV treatment have been set up using the well studied breast 
cancer cell line MCF7 as a template: 15 minutes of UV irradiation result optimal to 
induce DNA damage; the time point of 4 hours after irradiation results optimal for DNA 
repair pathway analysis. CCND1 siRNA silencing has been also assessed: 10 nM 
siRNA treatment for 48 hours results as the maximum silencing pick of cyclin D1 
protein. In IGROV1 cells, UV irradiation induces histone H2AX hyperphosphorylation 
on serine 139, marker of DSBs, and down-regulation of cyclin D1 in all the samples. 
UV-irradiated cells show up-regulation of RAD51 gene and formation of repair complex 
BRCA2-cyclin D1-RAD51 on damaged foci. 3l-treated cells show a depletion of cyclin 
D1 protein levels and irradiation of these 3l-treated cells induces DNA damage as 
normal. However, 3l-treated and then UV-irradiated cells do not present up-regulation 
of RAD51 gene and repair proteins colocalization. Anti-CCND1 siRNA silenced cells 
show comparable results to 3l-treated cells, while scramble siRNA silenced cells 
present comparable results to control cells. 
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This thesis confirms the important role of protein cyclin D1 in the repair pathway of 
DSBs: cyclin D1 participates in and it is essential for repair complex formation on 
damaged foci; cyclin D1 is also necessary for RAD51 gene up-regulation in case of 
DSB. The combined treatment of a drug leading to a depletion of cyclin D1 and a DNA 
damage inducer, such as irradiation, could be a potent potential therapy to target cancers 
with an elevated rate of DNA repair pathways, especially in case of chemo- and radio-
resistant tumours. 
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CHAPTER 1 
INTRODUCTION 
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The combined effects of DNA damage, DNA repair defects, and a failure to stall the 
cell cycle, lead to genomic instability, the most pervasive characteristic of cancer.
1
 
DNA damage can arise from many sources: endogenous (chemicals or radicals 
produced by the normal cellular metabolism) or exogenous (environmental such as 
radiations or pharmaceutical). All these genotoxic sources can manage to a variety of 
DNA damages as simple base modifications, base mismatches, bulky DNA adducts, 
inter-strand and intra-strand crosslinks, protein-DNA crosslinks, single-strand breaks 
(SSBs) or double-strand breaks (DSBs).
2
 
Given the potentially devastating effects of these varied and frequent DNA lesions, cells 
have evolved an intricate and complex series of mechanisms that counteract these 
threats to genomic integrity. Collectively, these mechanisms are known as DNA 
damage response (DDR) pathways.
1
 
DDR mechanisms are activated only for those cell types where repairing the damage is 
advantageous; otherwise apoptosis occurs.
3
 Cell death following DNA damage is a well 
regulated process during which the cell decides its outcome, determined by a threshold 
of pro-survival factors versus pro-death factors.
2
 
Of all these DNA damages, SSBs are the most common ones (roughly 10,000/day), they 
are mainly caused by endogenous reactive oxygen species (ROS) produced by cellular 
metabolism. SSBs are primarily repaired by the base excision repair (BER) mechanism: 
this pathway is extremely robust and it protects cells from both endogenous and 
exogenous stress (pollution, smoke, radiation). When they are not repaired, especially in 
proliferating cells, SSBs can lead to collapsed DNA replication forks and DSBs. 
However DSBs, the most lethal of all DNA lesions, are also normal events that occur 
during meiosis and somatic recombination. DSBs are repaired by endogenous 
mechanisms such as homologous recombination (HR) and non-homologous end joining 
(NHEJ). HR is error-free, while NHEJ is an error-prone mechanism. Interestingly, 
DSBs repair is dependent on the phase of the cell cycle: NHEJ is active during G0, G1, 
and early S cell cycle phases, whereas HR is most predominant during late S and G2 
phases, when DNA is already duplicated.
4
 
In Figure 1.1 all the possible DNA lesions are described in correspondence to DDR 
mechanisms, DDR involved proteins and tumour types induced in case of DDR 
dysfunction. 
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Figure 1.1: DNA lesions in relation to DNA damage repair mechanisms. 
Figure adapted from Lord, C Nature (2012)
1
 
The nucleotide excision repair (NER) is specific for repair of bulky adduct on DNA, 
while the mismatch repair (MMR) pathway is capable of repairing single base 
mismatches and a variety of small insertions and deletions in the genome. The repair of 
DNA inter-strand adducts are particularly problematic and employ the Fanconi anemia 
(FA) pathway, in collaboration with HDR.
3
 
DNA damage and the associated DDR pathways play a crucial role in carcinogenesis, as 
most oncogenic alterations such as mutations, translocations, amplifications, deletions, 
and epigenetic modifications are caused by the inefficient repair of damaged DNA.
4
 
There are several examples in which there is an indisputable link between a particular 
DDR pathway dysfunction and a neoplastic phenotype. For example, the analysis of a 
wide number of high-grade serous ovarian adenocarcinoma samples has estimated that 
nearly 50% of them is probably defective in the homologous recombination mechanism. 
These homologous recombination defects are mostly driven by DNA mutations or 
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epigenetic silencing of genes such as BRCA1 and BRCA2. Furthermore, sometimes the 
neoplastic condition exists because of a mutation in a gene that modulates the response 
to DSBs. This type of diseases include for example ataxia telangiectasia (ATM), 
Bloom’s syndrome and FA, all of which cause extreme radiosensitivity, a characteristic 
of the inability to process DSBs. It is thought that critical DSB signal transduction and 
cell cycle checkpoint proteins, such as ATM, ATM and Rad3-related (ATR), and the 
master gatekeeper protein p53 become inactivated to induce precancerous lesions to 
progress into mature tumours.
1
 
Historically, DDR defects have already been exploited therapeutically in the treatment 
of cancer with radiation therapies or genotoxic chemotherapies. For example, in patients 
with advanced ovarian cancer, platinum salts (carboplatin or cisplatin) are frequently 
used in combination with the taxane paclitaxel. Platinum salts cause DNA inter- and 
intra-strand crosslinks, lesions that are commonly repaired by NER and HR. These 
agents may be effective in patients with ovarian cancer because these tumours 
commonly harbour defects in HR, especially high-grade serous ovarian cancers.  
More recently, protein components of the DDR pathways have been identified as 
promising targets for cancer therapeutics. For instance, topoisomerase inhibitors, such 
as irinotecan (TopI inhibitor) and etoposide (TopII inhibitor), leave DNA breaks across 
the genome and have been used effectively in some cancers.
1,5
 
Furthermore, upregulated DDR mechanisms can cause resistance to DNA damaging 
chemotherapy and radiotherapy and so specific inhibitors of these pathways have the 
potential to sensitize cells to these therapies. For example, the high frequency of HR 
defects in tumours may provide a rationale for the use of inhibitors of HR to sensitize 
tumours with functional HR to conventional chemotherapy. There are few HR 
inhibitors: mirin is an inhibitor of MRE11 endonuclease activity, but its effects may not 
be specific to HR because it is involved in NHEJ, too. The activation of RAD51 by 
phosphorylation is an important step in HR and this step is dependent on the proto-
oncogene ABL1; for this reason the BCR-ABL1 inhibitor imatinib sensitizes cells to 
DNA crosslinking agents and IR. Other putative RAD51 inhibitors have been identified 
but the most common way to target HR remains the inhibition of the ATM–CHK2 or 
ATR–CHK1 pathways.6 
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1.1 DNA damage repair mechanisms 
1.1.1 Direct reversal 
Besides DDR pathways, nature has also evolved single enzyme mechanisms in which 
the damage is directly reversed by a single repair protein without the incision of DNA 
backbone. Although such direct repair processes mediate the reversal of a relatively 
small set of DNA lesions, they are relatively simple and essentially error-free.
7
 
There are two main types of direct DNA damage reversal: 
 repair of base alkylation by alkyltransferases and dioxygenases; 
 repair of UV-induced photolesions by photolyases.8 
In addition to BER pathway that corrects many N-alkylated lesions, other two direct 
pathways exist: O
6
-alkylguanine-DNA alkyltransferases (AGTs) reverse O
6
-alkylated 
guanines and AlkB family dioxygenases reverse mainly N-alkylated lesions blocking 
Watson-Crick pairings.
7
 
UV radiation produces mainly two types of DNA damages: the cyclobutane pyrimidine 
dimer (CPD) and the pyrimidine pyrimidones 6-4 photoproduct (6-4 PP). Photolyases 
are specific to either CPD or 6-4 PP lesion and they use blue and near-UV light to 
reverse UV-induced lesions. The study of these enzymes let Aziz Sancar get the Nobel 
Prize in 2015.
9
 
1.1.2 Base excision repair 
In 1974, Tomas Lindahl (Nobel Prize in 2015) identified a uracil DNA N-glycosylase 
(UNG), that excises uracil residues from DNA by cleaving the bond between uracil and 
deoxyribose. This was the starting point for the identification of the base excision repair 
(BER) pathway.
10
 
BER pathway evolved with the high level of spontaneous decay products that are 
formed in DNA, as well as those damages created upon reactions with natural 
endogenous chemicals, especially ROS. BER corrects small base lesions that do not 
significantly bulk the DNA double helix structure, such as deamination, oxidation, 
alkylation or methylation.
11,12
 
The repair pathway could be divided into these five following steps: 
 recognition and removal of the damaged base by a DNA glycosylase and 
creation of an abasic site; 
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 incision of the abasic site by an apurinic/apyrimidinic (AP) endonuclease or by 
an AP lyase; 
 removal of the remaining sugar fragment by a lyase or by a phosphodiesterase; 
 gap filling by a DNA polymerase; 
 sealing of the nick by a DNA ligase.13 
In humans BER is initiated by one of eleven damage-specific DNA glycosylases which 
display substrate specificity for particular types of damaged DNA bases: four devoted to 
the removal of mispaired uracil and thymine, six to the repair of oxidative damage, and 
one to the removal of alkylated bases. There are two different types of DNA 
glycosylases: monofunctional glycosylases (that recognize uracil, thymine, and 
alkylated bases) or bifunctional glycosylases (DNA glycosylase plus DNA strand 
cleavage activities).
14
 Monofunctional glycosylases employ a base-flipping mechanism 
to break the N-glycosidic bond between the damaged base and the phosphodiester DNA 
backbone, creating an AP site. The resulting abasic site is recognized by an AP 
endonuclease (APE1), which cleaves the abasic site leaving a sugar attached to the 5' 
side of the nick. The resulting 3' hydroxyl is a substrate for the repair polymerase, DNA 
polymerase β (Pol β), which also has a lyase activity that removes the sugar attached to 
the 5' phosphate. A complex consisting of DNA ligase III α (Lig IIIα) and X-ray cross-
complementing protein 1 (XRCC1) finally seals the remaining nick in the DNA 
backbone. Conversely, bifunctional glycosylases that recognize oxidative lesions excise 
the damaged base but also cleave the DNA backbone, leaving either an α, β unsaturated 
aldehyde or a phosphate attached to the 3' side of the nick. The sugar is removed by the 
phosphodiesterase activity of APE1 and the phosphate group by the polynucleotide 
kinase phosphatase (PNKP). This is the predominant process mode of BER and is 
commonly referred to as short-patch BER. In some circumstances the process can be 
redirected to a long-patch BER, often because the sugar is inefficiently removed from 
the 5' end of the nick; in these cases different DNA polymerases can take over, 
including the replicative polymerases δ or ε (Pol δ/ε). Pol δ/ε act by adding several 
nucleotides into the gap, generating a 5' flap structure which is excised by the flap 
endonuclease-1 (FEN-1) in a proliferating cell nuclear antigen (PCNA)-dependent 
process. Finally DNA ligase I (Lig I), always in concert with PCNA, seals the 
remaining nick in the DNA backbone (Figure 1.2).
11,15
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Figure 1.2: Base excision repair pathway. 
Figure from Carter, R J Mol. Cell. Biol. (2016)
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1.1.3 Nucleotide excision repair 
Nucleotide excision repair (NER) is the main pathway responsible for the removal of 
bulky lesions in the DNA. NER can be subdivided into two pathways: 
 global genome NER (GG-NER) can occur anywhere in the genome; 
 transcription-coupled NER (TC-NER) is responsible for the accelerated repair of 
lesions in the transcribed strand of active genes.
16
 
GG-NER is initiated by the recognition of the bulky lesion by the specific factor XPC 
complexed with RAD23B and centrin 2 (CETN2), in some cases with the help of UV-
DDB (UV-damaged DNA-binding protein). The XPC-RAD23B-CETN2 complex melts 
the DNA around the lesion and recruits the multiprotein complex TFIIH. A stalled RNA 
polymerase (RNA Pol II) constitutes the first step of TC-NER. The blocked complex 
recruits CSB, a transcription elongation factor, and other specific factors as CSA and 
XAB2, that translocate along template DNA with RNA Pol II. The UVSSA protein and 
its partner USP7 are transiently associated with elongating RNA Pol II but, in case of 
10 
 
transcription arrest, they bind more strongly and stabilize CSB. Both subpathways 
converge when TFIIH (transcription initiation factor II H) is recruited to the repair site 
(Figure 1.3).
17
 
  
Figure 1.3: Nucleotide excision repair pathway. 
Figure adapted from Marteijn, J A Nat. Rev. Mol. Cell. Biol. (2014)
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Then, the XPG structure-specific endonuclease binds to the pre-incision NER complex 
and the CAK (CDK-activating kinase) subcomplex dissociates from the core TFIIH 
complex. TFIIH comprises ten proteins, one of them is the ATPase helicase XPB: the 
helicase activity of TFIIH further opens the double helix around the lesion, creating a 
20-30 nucleotide bubble. Another ATPase helicase complex protein, XPD, detects and 
verifies the existence of lesions. Once the pre-incision complex is assembled, XPA, 
RPA, and XPG are recruited. XPA binds to the altered single-stranded DNA; RPA 
(replication protein A) coats the ssDNA opposite the lesion, protecting it from 
degradation and helping to coordinate excision and repair events. XPA recruits the 
heterodimer structure-specific endonuclease ERCC1-XPF, which is directed to the 5' 
11 
 
end of the bubble. XPG is then activated and cuts the damaged strand 3' to the lesion 
and it excises the lesion within a 22-30 nucleotide-long strand. The proliferating cell 
nuclear antigen (PCNA) ring, which is directly loaded after the 5' incision by ERCC1-
XPF, recruits DNA Pol δ, Pol κ or Pol ε for the filling of the created gap. Pol ε is active 
in replicating cells, while Pol δ/κ are the main NER polymerases in non-replicating 
cells. NER pathway is completed through sealing of the final nick by DNA ligase I (in 
replicating cells) or XRCC1-ligase III (in quiescent cells).
17,18
 
1.1.4 Mismatch repair 
DNA mismatch repair (MMR) is a highly conserved biological pathway that plays a key 
role in maintaining genomic stability, in fact inactivation of this repair system confers a 
large increase in spontaneous mutations and a strong predisposition to tumour 
development. MMR research conferred to Paul Modrich the Nobel Prize in 2015.
19
 
The specificity of MMR is primarily for base-base mismatches and insertion/deletion 
mispairs generated during DNA replication and recombination. MMR also ensures the 
fidelity of genetic recombination, and participates in the earliest steps of damage 
signaling in eukaryotic cells.
20
 
MMR repair is a strand-specific process. During DNA synthesis, if the newly 
synthesised strand includes errors, this repair machinery can distinguish the new strand 
from the methylated template (in prokaryotes). In eukaryotes, the newly synthesized 
lagging-strand DNA transiently contains nicks, before being sealed by DNA ligase, and 
for this reason it provides a signal that directs mismatch proofreading systems to the 
appropriate strand.
21
 
These nicks are sites for the RFC-dependent loading of the replication sliding clamp 
PCNA, in an orientation-specific manner. Oriented PCNA then directs the action of the 
endonucleases MutS, MutH and MutL, forming the MutSHL complex, which remove 
the wrong nucleotides. The removal process involves more than just the mismatched 
nucleotide itself: a few or up to thousands of base pairs of the newly synthesized DNA 
strand can be removed.
22 
The entire process ends when the single-strand gap created is repaired by DNA Pol III 
that uses the other strand as a template, with the help of the single-strand DNA-binding 
protein SSB. Finally, the nick is sealed by a DNA ligase.
23
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1.1.5 Repair of DNA double-strand breaks 
DNA double-strand breaks (DSBs) are cytotoxic lesions generated when the phospho-
sugar backbones of both strands of DNA are broken at the same position. Among DNA 
damages, DSBs are considered to be lethal within the cells because failure to repair a 
DSB has deleterious consequences, including chromosomal rearrangements, such as 
translocations and deletions, and resulting in oncogenic transformation or cell death. In 
contrast to DNA single-strand breaks (SSBs), in which the genetic information is 
retained on the complementary strand, repair of DSBs can be problematic. Obviously, 
DSB repair must restore both the physical integrity of the chromosome and its genetic 
information.
24
 
DSBs can be generated by physiological processes as recombination or exogenous 
agents as radiations or chemicals. These include base alkylating agents such as methyl 
methane sulfonate (MMS), as well as intra- or inter-crosslinking agents, including 
mitomycin C, platinum derivatives and nitrogen mustards. Drugs that generate DSBs 
are widely used in cancer treatment since tumor cells are often more sensitive to DSBs 
than normal cells. DNA topoisomerase inhibitors induce the formation of SSBs or DSBs 
by trapping topoisomerase-DNA intermediates during isomerization reactions. For 
example, camptothecin, irinotecan and topotecan inhibit type I topoisomerases, 
generating DSBs primarily during DNA replication. Meanwhile, etoposide, 
mitoxantrone, teniposide and doxorubicin inhibit type II topoisomerases, generating 
DSBs throughout the cell cycle. Ionizing radiations (IR) and ultraviolet radiation (UV, 
especially UV-B) are generators of DSBs, furthermore radiations produce DSBs 
because they induce reactive oxygen species (ROS). ROS are also generated during 
normal cellular metabolism, they can oxidize bases and induce both single- and double-
strand breaks. Physiological sources of endogenous DSBs include DNA replication and 
meiotic recombination, that are the major causes of DSBs in proliferating cells because 
of fragile and breakable DNA intermediates. Clearly, breaks can occur following 
replication stalling forks, which leads to the generation of persistent single-strand DNA 
intermediates.
25,26
 
The repair of DSBs involves two major possible mechanisms: non-homologous end 
joining (NHEJ) and homologous recombination (HR). In NHEJ the DSB is repaired by 
blunt end ligation in a sequence homology-independent way. In contrast, HR requires 
13 
 
extensive homology for the repair of DSBs, in fact HR plays a major role during the S 
and G2 phases of the cell cycle, when the template homologous sister chromatids are 
available.
27,28
 
1.1.5.1 Non-homologous end joining 
While the template-independent nature of non-homologous end joining (NHEJ) 
suggests its error-prone characteristic, it is a highly faithful mechanism, with an error 
rate of about 10
-3
 per joining event between fully compatible DSB ends.
29
 
NHEJ repair pathways are subdivided into the canonical non-homologous end joining 
pathway (c-NHEJ), which is dependent on Ku proteins and DNA ligase IV, and a group 
of less well elucidated alternative pathways (alt-NHEJ), dependent on DNA ligase I/III 
(Figure 1.4). 
 
Figure 1.4: Non-homologous end joining repair pathway. 
Figure from Lazzerini-Denchi, E Nat. Rev. Mol. Cell. Biol. (2016)
30
 
C-NHEJ begins when the Ku70-Ku80 heterodimer binds to DNA ends with high 
affinity. Ku dimer then recruits the Ser/Thr kinase DNA-dependent protein kinase 
catalytic subunit (DNA-PKcs) to phosphorylate a number of downstream targets, 
14 
 
including the terminal end-processing enzyme Artemis. Artemis cleaves single-stranded 
overhangs and the complex XRCC4-LIG4 (DNA ligase IV) seals DNA ends.
31
 
Alt-NHEJ is dependent on poly(ADP-ribose) polymerase 1 (PARP1) signaling and it 
depends on DNA 5'-3' resection by the MRN complex (constituted of MRE11-RAD50-
NBS1) and CtIP (CtBP-interacting protein). Base pairing at the resected ends drives 
their annealing to promote synapsis of opposite ends of the DSB. The low-fidelity DNA 
polymerase θ (Pol θ) fills the annealed ends, and finally LIG1/3 (DNA ligase I/III) seals 
them. Alt-NHEJ is a more error-prone pathway in comparison to c-NHEJ: it introduces 
deletions caused by extended nucleolytic processing and insertions caused by the 
activity of Pol θ.32 
1.1.5.2 Homologous recombination 
The homology-directed repair (HDR) is a mechanism highly evolutionarily conserved 
from prokaryotes to humans (Figure 1.5). It operates on the same principles of 
homologous recombination (HR): the ends of a DSB are recognized and processed to 
generate 3' single-stranded DNA overhangs, through a process termed DNA end 
resection. It provides an important mechanism to repair both accidental and 
programmed DSBs during mitosis and meiosis, especially in S/G2 phases of the cell 
cycle, where it promotes an error-free repair thanks to the template sister chromatid.
33
 
HDR is accompanied by histone modifications, like γH2AX, and chromatin remodeling. 
Phosphorylation on serine 139 of histone H2AX (γH2AX) is one of the most important 
markers of DSBs and it is involved in the induction of repair signaling.
34,35
 
The central reaction in HR and in HDR is the pairing and exchange of strands between 
two homologous DNA molecules. First of all, DNA ends are processed to yield 3' 
single-stranded DNA tails. In humans, this 5'-3' end resection occurs thanks to MRE11-
RAD50-NBS1 (MRN) complex and CtIP which clip 5' ends of DNA and thanks to 
EXO1 or BLM-TopoIIIα-RMI1 and DNA2 which process the early intermediate to 
form extensive regions of single-stranded DNA. In accordance, the replication protein A 
(RPA) binds the single-stranded DNA tails until RAD51 is recruited by BRCA2-
PALB2 and forms a helical nucleoprotein filament around the single-stranded DNA. 
Once formed, the complex RAD51-ssDNA searches for a homologous sequence and 
then promotes invasion of the single-stranded DNA into donor double-stranded DNA to 
form a joint molecule with a displaced strand, called D-loop.
36,37
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Figure 1.5: Homologous recombination pathway in DNA double-strand break repair. 
Figure from Mazón, G Cell (2010)
38
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RAD54, a member of the Swi2/Snf2 family of chromatin remodeling proteins or 
ATPases, stimulates homologous pairing and DNA polymerase δ/η extends the 3' end 
from the broken chromosome using the donor strand as a template and replacing 
nucleotides lost by end resection. Here, the D-loop can be resolved by different paths.
39
 
In the (SDSA) path, the invading strand that has been extended by DNA synthesis is 
displaced (strand displacement) and it anneals to complementary sequences exposed by 
5'-3' resection of the other side of the break (strand annealing). The RTEL1 helicase can 
dissociate D-loop intermediates to facilitate SDSA. The synthesis-dependent strand 
annealing forms exclusively noncrossover products.
40
 
In the canonical repair path (double-strand break repair, DSBR), the other end of the 
break interacts with the displaced strand of the D-loop (second end capture) and the 3' 
end primes DNA synthesis, forming a double Holliday junction (dHJ) intermediate 
(double Holliday junction formation). Then, the dHJ intermediate can be dissolved or 
resolved to give two intact double-stranded DNA molecules. Dissolution requires the 
activity of the BLM-TopoIIIα-RMI1 helicase complex, which drives migration of the 
constrained dHJ and decatenates the interlinked strands between the two Holliday 
junctions, yielding noncrossover products. Otherwise, resolution through nucleolytic 
cleavage of the dHJ can give both crossover or noncrossover products: crossovers form 
from the cut of the inner strands of one Holliday junction and of the outer strands of the 
other Holliday junction; while noncrossovers are produced by cutting both junctions in 
the same plane. Following cleavage of dHJ, the ends are ligated to complete the 
reaction. In humans, resolvases implicated in this resolution are MUS81-EME1, GEN1, 
SLX1-SLX4, XPF-ERCC1.
41
 
In the last possible path, the extended D-loop structure could be cleaved prior to 
formation of a mature dHJ intermediate (early D-loop cleavage). MUS81-EME1 
nuclease could promote crossover formation by cleaving the strand invasion 
intermediate directly.
42
 
1.1.6 Fanconi anemia 
The Fanconi anemia (FA) repair pathway is required for genome protection against 
inter-strand crosslinks (ICLs). This type of lesions are considered ones of the most 
deleterious DNA lesions, because two Watson and Crick strands of DNA are covalently 
bound together, obstructing both replication and transcription. ICLs can be generated by 
17 
 
naturally occurring compounds, chemotherapeutic agents or during normal cellular 
metabolism. ICLs left unrepaired can lead to mutations, chromosome breakage, 
chromosome missegregation and mitotic catastrophe. The FA family of proteins 
includes 19 distinct functional complementation groups whose gene products suppress 
ICL sensitivity. Mutations in most FA genes in normal cells lead to a chromosomal 
instability disorder characterized by multiple developmental abnormalities, progressive 
bone marrow failure and cancer predisposition, which underlie the pathologies 
associated with Fanconi anemia.
43,44
 
When two convergent replication forks collide and stall at an ICL site, BRCA1 acts to 
dismantle the replisome and RAD51 binds to the single-stranded DNA to protect the 
fork. Subsequent FANCM-FAAP24-MHF1/2 complex binding activates ATR signaling 
pathway and promotes recruitment of the FA core complex. The FA core complex in 
turn ubiquitinates the FANCI–FANCD2 heterodimer, which acts as a platform to recruit 
multiple nucleases like XPF-ERCC1, SLX1-SLX4, MUS81-EME1, FAN1, SNM1A, 
and SNM1B. Nucleolytic incisions unhook the ICL and facilitate translesion synthesis-
dependent lesion bypass, mediated by REV1 or Pol ζ polymerase. Finally, the generated 
double-strand break is repaired by homologous recombination.
45,46
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1.2 Cyclin D1 
The D-type cyclin family is composed of three proteins (cyclin D1, cyclin D2 and 
cyclin D3) that are expressed in proliferating cells. They are closely related: the human 
cyclin D2 and D3 proteins are 62% and 51%, respectively, identical to human cyclin 
D1, and 62% identical to each other. Alternative splicing can arise to another cyclin D1 
isoform, cyclin D1b: it diverges from the canonical full-length cyclin D1 protein at the 
carboxy-terminal because it lacks some key interaction domains (Figure 1.6).
47
 
 
Figure 1.6: Domain structure of D-type cyclins family. 
Figure from Musgrove, E Nat. Rev. Cancer (2011)
47
 
The greatest homology in the D-type family of cyclins occurs in the cyclin box that 
mediates cyclin-dependent kinase (CDK) binding and is important for the interaction 
with CIP/KIP family of CDK inhibitors as p21, p27 and p57. Retinoblastoma (RB) 
protein-binding domain (characterized by the LXCXE motif) is always present at the 
extreme amino-terminal. At the carboxy-terminal there is a highly conserved PEST 
domain that is rich in proline, glutamate, serine and threonine and that is characteristic 
of proteins that are rapidly turned over. If threonine 286 in cyclin D is phosphorylated, 
the protein is sent to ubiquitin-mediated degradation; this phosphorylation also 
promotes cyclin D1 nuclear export. Mutations within these highly conserved regions 
have been widely used to probe cyclin D1 functions. The region between the cyclin box 
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and the carboxy-terminal is relatively poorly conserved and it contains domains that are 
responsible for transcription factor-cyclin D1 interactions. In cyclin D1, the leucine-rich 
motif LLXXXL at the carboxy-terminal is designated to the binding of the steroid 
receptor co-activators SRC1 and AIB1.
47
 
The earliest known and best understood function of cyclin D1 is to promote cell 
proliferation as a regulatory partner for CDK4 or CDK6 but, recently, there is growing 
evidence that cyclin D1 plays cell cycle-independent roles that are also independent of 
CDKs substrate phosphorylation (Figure 1.7). 
 
Figure 1.7: CDK-independent functions of cyclin D1. 
Figure from Musgrove, E Nat. Rev. Cancer (2011)
47
 
Extracellular signals, such as growth factors and integrin-derived adhesion signaling, 
influence cyclin D1 transcription, translation and degradation, integrating mitogenic, 
differentiation and adhesion signaling with the cell cycle regulatory machinery. The 
deregulation of cyclin expression or CDK activation can directly lead to cancer by 
causing proliferation or by overriding checkpoints that ensure genomic integrity and 
stability. Furthermore, the gene encoding cyclin D1 (CCND1) represents the second 
most frequently amplified locus in the human cancer genome. The oncogenicity and 
multiplicity of cyclin D1 effects on cancer cell biology, and evidence for its CDK-
independent actions on end points such as cell migration and the DNA damage 
response, provide an impetus for targeting cyclin D1 rather than, or in addition to, 
CDK4/CDK6 activity.
48,49
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1.2.1 Cyclin D1 in cell cycle regulation 
The cell cycle is a complex process that controls cell growth and proliferation; it is also 
involved in development, regulation of DNA damage and diseases such as cancer. The 
cell cycle is divided into phases. The first phase, G1 gap, is the preparation of the cell 
for DNA synthesis that occurs in the second phase, the S one. The third phase is the G2 
gap in which the cell prepares for mitosis, that occurs in the fourth phase, the M one. 
There is also an additional G0 gap that is the phase in which cells are not cycling. 
Regulatory proteins can direct the cell through a specific sequence of events that go 
towards mitosis: these important proteins are cyclin-dependent kinases (CDKs) and 
cyclins. In general, the cell can go through cell cycle phases only if the specific cyclin 
binds and activates the specific phase CDK. CDKs are serine-threonine kinases that are 
regulated by phosphorylation on threonine and tyrosine residues. Cyclins have a cyclic 
expression because they are regulated by ubiquitination-mediated proteolysis: for this 
reason CDKs can be activated only at specific times during the cell cycle. The cell can 
enter in the next phase only if the appropriate cyclin of the previous phase is degraded 
and the cyclin of the next phase is synthesized. Cyclins target CDKs to the nucleus 
because they contain nuclear localization signals. In the nucleus, CDKs phosphorylate a 
variety of substrates that are necessary for cell proliferation. Cell cycle checkpoints are 
essential for the cell to monitor and regulate its progress through the cycle. They 
prevent cell cycle progression at specific points, allowing verification of necessary 
phase processes and repair of DNA if it is damaged. The cell proceeds to the next phase 
only if checkpoint requirements have been met. Several checkpoints are designed to 
ensure that damaged or incomplete DNA is not passed on to daughter cells. Three main 
checkpoints exist, but D-type cyclins control only G1/S transition, also known as 
restriction point.
50
 
The restriction point is controlled by CDK4/CDK6 proteins that have to bind to cyclin 
D proteins. This active complex can phosphorylate the target protein retinoblastoma 
(RB) on multiple residues. RB normally binds to the transcription eukaryotic factor 2 
(E2F), making it unavailable for transcription. When RB protein is phosphorylated by 
the specific CDK, E2F is free to act as a transcription factor for the expression of genes 
required for nucleotides biosynthesis, DNA synthesis, mitotic progression and DNA 
damage repair (Figure 1.8).
51
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Figure 1.8: Cyclin D1 functions in cell cycle regulation (A) and DNA repair (B). 
Figure from Jirawatnotai, S Cancer Res. (2012)
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The RB-E2F complex can also repress transcription by a different mechanism: RB may 
also inhibit E2F by recruiting chromatin remodeling enzymes, including histone 
deacetylases (HDACs). HDACs are a family of at least seven different enzymes that 
remove acetyl groups from the tails of histone octamers, facilitating nucleosomal 
compaction and negatively affecting accessibility of transcription factors to promoters. 
In addition, it is possible that RB-mediated recruitment of HDAC to E2F also acts by a 
repression of the activity of histone acetyltransferases (HATs) that are complexed to 
E2F.
52
 
Furthermore, association of D-type cyclins to CDK4/CDK6 is influenced by important 
negative regulators such as the INK4 family of CDK inhibitors (p15, p16, p18, p19) and 
a second family of molecules, CIP/KIP inhibitors, containing p21, p27 and p57. In 
general, these proteins inhibit CDK association with its cyclin, preventing complex 
formation.
53
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1.2.2 Cyclin D1 in DNA damage repair 
As already explained before, cyclin D1 protein has been recently shown to have an 
important role in DNA damage repair: after DNA damage by radiation or 
chemotherapeutics, cyclin D1 protein levels are significantly reduced and the cell cycle 
is arrested. Part of the remaining pool of cyclin D1 is recruited into the nucleus, to DNA 
damage sites, in a BRCA2-dependent manner, to facilitate and stabilize RAD51 
localization, thereby assisting the homologous recombination (HR)-mediated DNA 
repair pathway (Figure 1.8).
51,54 
One of the first who elucidated this new function of cyclin D1 were Siwanon 
Jirawatnotai et al. in 2011: they performed a proteomic screen for cyclin D1 partners in 
order to elucidate the molecular functions of this protein. They analysed four types of 
human tumors, all overexpressing cyclin D1 gene CCND1: mantle cell lymphoma 
(Granta 519 cells), breast cancer (MCF7 and ZR-75-1), squamous cell carcinoma 
(UMSCC-2), and colorectal cancer (HT-29). Cyclin D1-containing complexes were 
purified using double immunoaffinity purification, and the identity of cyclin D1 
interactors was determined by rounds of liquid chromatography and high-throughput 
mass spectrometry (LC-MS/MS). Finally, with the total 132 proteins identified with 
high confidence, they constructed a biological process/molecular function enrichment 
heatmap of cyclin D1 interactors. Apart from cell cycle control proteins, unexpectedly, 
they observed DNA repair category amongst the most enriched functions. A cluster of 
DNA repair proteins centered on RAD51, the DNA recombinase mediating DNA repair 
via homologous recombination, was identified. These observations first suggested that 
cyclin D1 may play a key role in DNA damage repair (Figure 1.9). They also observed 
that if you silence CCND1, there is a significant increase in the sensitivity of cancer 
cells to ionizing radiation (IR) and to DNA damaging drugs as topoisomerase inhibitors. 
Re-expression of cyclin D1 in these cells restored radiation sensitivity. Furthermore, 
treatment with a specific inhibitor of CDK4/6 kinase had no effect on sensitivity of 
cancer cells to radiations; for this reason, cyclin D1 might play a kinase-independent 
function in DNA repair. They found that radiation induced comparable levels of DNA 
damage in control and in cyclin D1-depleted cells but that, at 16 hours post-radiation, 
more unrepaired DNA persisted in cyclin D1-depleted cells.
55
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Figure 1.9: Interactome map of cyclin D1 according to biological process. 
Figure from Jirawatnotai, S Nature (2011)
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They showed how, in some cells, depletion of cyclin D1 significantly reduced 
homologous recombination and re-expression of cyclin D1 rescued this effect. To 
investigate the function of cyclin D1 in HR, they analyzed the interaction of cyclin D1 
with RAD51. They established that the amino-terminus of cyclin D1 directly binds to 
the carboxy-terminus of RAD51 and that this interaction is induced by radiation. 
RAD51 and cyclin D1 are recruited and colocalize at the sites of double-stranded DNA 
breaks (DSBs), characterized by histone H2AX phosphorylated on serine 139 (γH2AX). 
They reported that knock-down of CCND1 resulted in reduced recruitment of RAD51 to 
DNA damage foci. With these results, they demonstrated how cyclin D1 helps to recruit 
RAD51 through a direct cyclin D1-RAD51 physical interaction. Then, in this paper they 
verified the direct interaction of cyclin D1 with BRCA2 and reported that BRCA2 is 
essential for recruitment of cyclin D1, consistent with the notion that BRCA2 acts 
upstream. Collectively, these results are consistent with the DNA damage repair model 
of cyclin D1: cyclin D1 is recruited to DNA damage sites through BRCA2 and then it 
helps to recruit RAD51 through a direct cyclin D1-RAD51 interaction. In fact, depletion 
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of cyclin D1 reduces RAD51 recruitment and reduces RAD51-BRCA2 colocalization at 
DNA damage sites, leading to impaired homologous recombination. Moreover, cyclin 
D1 is not required for recruitment of FANCD2, FANCI, PCNA, MSH6, BRCA1 and 
MRE11. Jirawatnotai et al. also observed that, upon irradiation, cyclin D1-depleted 
tumors displayed in vivo retarded growth as compared to control tumors, revealing 
increased sensitivity to IR. By all these findings, there is great evidence about cyclin D1 
as a possible target to sensitize human cancers to radiation, by limiting DNA repair. 
Thus, targeting cyclin D1 in combination with radiation treatment may have potential 
therapeutic value in a large pool of cancers.
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Zhiping Li at al. in 2010 already assessed the importance of full-length cyclin D1 
protein for a correct DNA damage response. The canonical cyclin D1 isoform (cyclin 
D1a), but not cyclin D1b, contributes at the recruitment of DNA repair factors at 
γH2AX foci. They also suggested a possible implication of cyclin D1 in the induction of 
expression of DNA repair proteins, such as RAD51.
56
 Afterwards, the same group 
verified that cyclin D1 is required for both basal and estrogen-induced expression of 
RAD51 gene and they hypothesized a model (Figure 1.10).
57
 
 
Figure 1.10: Model for cyclin D1-dependent induction of homology-directed repair. 
Figure from Li, Z Cancer Res. (2014)
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In this model cyclin D1, associated with ERα in the cytoplasm, augments AKT 
signaling and is essential for γH2AX foci formation. Cyclin D1 increases homologous 
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recombination-mediated repair (HDR), in part through binding to DNA at γH2AX foci 
and through inducing RAD51 recombinase transcription and abundance.
57
 
In addition, cyclin D1 binds RAD51 but it does not directly recruit it: cyclin D1 just 
enhances RAD51 binding to BRCA2 because it prevents the inhibitory BRCA2 serine 
3291 phosphorylation. BRCA2 accumulates RAD51 molecules on its RAD51-binding 
motifs: the BRC repeat domain is in the middle portion of the protein, while the other 
conserved motif is at the carboxy-terminal domain of BRCA2. BRCA2 carboxy-
terminal mutants, such as BRCA2 6174delT and 6158insT, lack the functional RAD51-
binding domain and exhibit reduced capacity to recruit RAD51 to DNA damage foci; in 
such manner these mutants present limited DNA repair and these mutations are 
characteristic of various human cancers, like pancreatic, breast or ovarian cancer. 
Normally, HR pathway factors, including CtIP/SAE2, NBS1 and BRCA2, are substrates 
for CDKs, underlining the direct role of cell cycle proteins in the DNA repair process. 
Cyclin A-CDK2 and cyclin B-CDK1 can phosphorylate BRCA2 on serine 3291, on the 
carboxy-terminal RAD51-binding domain. Under DNA damage conditions, BRCA2 is 
dramatically hypophosphorylated because of the degradation of CDC25A and the rapid 
decline of CDKs activity; thereby BRCA2 can recruit RAD51 and DNA is repaired. 
Aminoacids 90-155 of cyclin D1 directly interact with RAD51, but cyclin D1 is not 
necessary for BRCA2 recuitment at damaged foci. Altogether, these findings suggest 
that cyclin D1 facilitates RAD51 recruitment to BRCA2-bound DNA damage foci. It is 
reported that cyclin D1 (aminoacids 20-90) interacts directly with the carboxy-terminus 
(aminoacids 3189-3418) of BRCA2, and it impedes the inhibitory cyclin A/B-CDK2/1-
dependent BRCA2 phosphorylation. In this way, cyclin D1 indirectly facilitates RAD51 
recruitment and HDR-mediated DNA repair. Cyclin D1, which preferably interacts with 
the hypophosphorylated form of BRCA2, accumulates at the carboxy-terminal domain 
and precludes kinase from this site. These statements underline how in wild-type 
BRCA2 cancers, targeting cyclin D1 in combination with DNA damaging agents may 
be beneficial for the cancer treatment.
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In the last two years, some papers showed the importance of targeting cyclin D1 in 
prostate cancer cells, multiple myeloma tumours and mantle cell lymphoma cell 
lines.
59,60
 Prostate cancer cells are frequently characterized by an elevated DNA repair 
capacity that leads to radiation resistance. Cancer cells escape from radiation therapy by 
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repairing the DNA lesions through the activation of highly conserved enzymatic 
pathways: only the accumulation of unrepaired breaks may generate chromosomal 
aberrations that, after a variable number of cell cycles, induce cell death. Silencing 
CCND1 affects the tumorigenic potential of prostate cancer cell lines in vitro and in 
vivo; in addition migration and invasion abilities are drastically reduced in the absence 
of cyclin D1. The radiosensitization induced by silencing cyclin D1 is dependent on the 
increased accumulation of double-stranded breaks (DSBs).
61
 In mantle cell lymphoma 
cells, CCND1 depletion results in DSBs and genomic instability during DNA 
replication. The genome protective function of cyclin D1 is thus relevant to the 
resistance of mantle cell lymphoma to chemotherapeutic agents.
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Activation of DSBs repair genes is one of the reasons for chemo- and radio-resistance, 
therefore, targeting DNA repair pathways is an attractive strategy to eliminate cancer. 
Currently, there are no small-molecule inhibitors of CCND1 under clinical 
development, but pharmacologic agents that indirectly reduce CCND1 levels have been 
reported.
61
 
1.2.3 Cyclin D1 in chromosomal instability 
As cyclin D1 expression is increased in the early phases of tumorigenesis, it may be an 
important inducer of chromosomal instability (CIN) in tumors. Cyclin D1 induces CIN 
in different types of cells: cyclin D1 overexpression correlates with aneuploidy, 
polyploidy, supernumerary centrosomes, and spindle defects. ChIP-seq analysis have 
shown how cyclin D1 is bound and enriched on genes that govern CIN. For this reason, 
cyclin D1 contributes to chromosomal instability and tumorigenesis by directly 
regulating a transcriptional program that governs CIN.
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Some speculations were drawn on the indirect DNA damaging effect of overexpressed 
cyclin D1. Cyclin D1 or cyclin D1b variant overexpressions are a consequence of 
CCND1 gene mutations or genetic variations. Overexpression of cyclin D1 might force 
a premature S phase entry, accumulating DNA lesions, might antagonize cell cycle 
arrest signal, promote hyperactive homologous recombination repair, and facilitate 
transcriptional activation of genes that interfere with genome stability. Overexpression 
of cyclin D1 also drives cancer cells bearing DNA lesions to undergo clonal expansion 
(Figure 1.11).
64
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Figure 1.11: Overexpression of cyclin D1 induces genome instabiliy and cancer 
formation via different indirect mechanisms. 
Figure from Jirawatnotai, S DNA Repair (Amst). (2016)
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1.2.4 Cyclin D1 in cell migration 
Metastasis is the major cause of death in cancer patients and cellular migration is 
essential for tumor metastasis. Cyclin D1 induces cell migration in a CDK-dependent 
manner as some CDK4/CDK6 substrates have roles in cell adhesion, cell migration, and 
cytoskeletal remodeling. Phosphorylation of these substrates such as filamin A and Ral 
GEF Rgl2 contributes to enhanced cell detachment and motility. Cyclin D1 induces cell 
migration also in a CDK-independent manner: it binds p27 and it inhibits RhoA GTPase 
activity. In addition, cyclin D1 promotes cellular migration by transcriptional 
upregulation of ROCKII and thrombospondin (TSP-1). The frequent amplification and 
overexpression of cyclin D1 in cancer cells suggest that cyclin D1 may have a central 
role in mediating the invasion and metastasis by controlling Rho/ROCK signaling and 
expression of TSP-1. In fact, if cyclin D1 is depleted, macrophages, fibroblasts, and 
epithelial cells have enhanced adhesion and decreased motility.
65,66
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Ovarian cancer is the most common cause of gynecological cancer-associated death. 
Epithelial ovarian cancer can be subdivided into different histological subtypes, but 
high-grade serous carcinoma (HGSC) is the most commonly diagnosed. Globally, 
225,500 new cases of ovarian cancer are diagnosed each year. In the United States, 
approximately 22,280 new cases occur annually and the projected number of deaths for 
2016 is 14,240. Survival varies greatly based on stage at initial diagnosis: 5-year overall 
survival in patients with stage I cancer is 92.1%, but it is 25% for patients with stage III 
and stage IV cancers. Effective screening strategies for the early detection of ovarian 
cancer do not exist, but individuals at high risk of developing ovarian cancer, such as 
those with germline mutations in BRCA1 or BRCA2 genes, can be identified. The most 
active therapeutic agents against ovarian cancer are platinum analogues (either cisplatin 
or carboplatin), with the addition of a taxane (either paclitaxel or docetaxel). Treatment 
paradigms for first-line management of newly diagnosed ovarian cancer include either 
primary surgical cytoreduction followed by platinum-based chemotherapy or 
neoadjuvant chemotherapy followed by interval surgical reduction and additional 
chemotherapy.
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The most difficult issue in the treatment of ovarian cancer is the eventual development 
of platinum resistance. A small population of platinum-resistant cancer cells exists in 
ovarian tumours before treatment and flourishes once treatment has killed their 
platinum-sensitive counterparts. This results in regrowth of the tumour, and a low 
probability that it will respond to further treatment with platinum-based drugs. 
Advances in new therapeutics for recurrent ovarian cancer treatment include 
angiogenesis inhibitors, immunotherapy agents, selective estrogen receptor modulators 
(SERMs), and finally inhibitors of DNA damage repair mechanisms, such as poly(ADP-
ribose) polymerase (PARP) inhibitors. Strategies using PARP inhibitors as part of the 
first-line treatment, as well as combinations of these therapies for the treatment of both 
newly diagnosed and recurrent ovarian cancer, are underway.
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Most subtypes of epithelial ovarian cancer are associated with germline BRCA 
mutations. Survival is improved for women with ovarian cancer carrying germline 
BRCA mutations compared with wild type BRCA1 and BRCA2, probably because 
BRCA2 mutation results in enhanced platinum sensitivity. Besides BRCA1 and BRCA2, 
other germline mutations in genes involved in DNA repair can increase the risk of 
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developing ovarian cancer, including RAD51 and PALB2. Inherited mutations in other 
genes involved in DNA repair, such as CHEK2, MRE11A, RAD50, ATM and TP53, 
might also increase the risk of developing ovarian cancer.
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Scope of this thesis is to find a new possible approach for the treatment of ovarian 
cancer. 
The model in this study is IGROV1, a human ovarian tumor-derived cell line with 
epithelial morphology, endometrioid histology for the major part of the tumor, with 
some serous clear and undifferentiated cells. IGROV1 cells are at grade 2 and stage III, 
with a doubling time of 27 hours. TP53, BRCA1 and BRCA2 genes are mutated, but 
BRCA2 mutation is silent; in total there are three mutated genes in the homologous 
recombination repair pathway.
69,70
 
This study tries to set a combined treatment to increase sensitivity of IGROV1 cells 
to irradiation. 
3l is an E-3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2one (Figure 2.1) that has 
been synthesized by Professors Rambaldi and Locatelli’s research group at Pharmacy 
and Biotechnology (FaBiT) Department of the University of Bologna.
71
 
 
Figure 2.1: Structural formula of molecule 3l. 
It has been published that 3l has a cytostatic, but not cytotoxic, effect on leukemia, 
central nervous system, ovarian, renal, prostate and breast cancer cell lines. In ovarian 
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cancer cell lines, 3l has a pGI50 of 5.45 that corresponds to 3.5 µM treatment 
concentration. 3l 5 µM treatment of IGROV1 cells induces a retained block in cell 
proliferation with cell cycle arrest in G0/G1 phases.
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Furthermore, Professor Calonghi's group has showed how 3l induces a strong 
irreversible growth arrest characterized by progressive accumulation of IGROV1 cells 
in G0/G1 phases, and such cells reach nearly synchronization after 72 hours of 
treatment. With an excitation and an emission wavelengths of 488 nm and 530 nm, 
respectively, 3l can be visualized by fluorescence-based methods. Confocal microscopy 
experiments revealed that 3l is already localized in the nucleus after 6 hours of 
treatment and that the 3l fluorescent signal colocalizes with the estrogen receptor β 
(ERβ), but not with the estrogen receptor α (ERα). Interestingly, the 3l-ERβ complex is 
bound to chromatin. Transcription analysis by quantitative Real-Time PCR (qRT-PCR) 
reported no changes in ERα target genes. Additional chromatin immunoprecipitation 
(ChIP) experiments of ERα binding to pS2 promoter, a well known ERα target gene, 
showed that this event is not modified by 3l treatment, confirming that this nuclear 
receptor is not involved in 3l mechanism of action. After 6 hours of treatment with 3l, 
transcription analysis showed a decrease in CCND1 gene expression, an increase in p16, 
whereas ERβ and p21 gene expressions did not change. After 24 hours of treatment, 
analysis showed a further decrease in CCND1 gene expression; ERβ gene expression 
was up-regulated, but not that of p16. The analysis of ERβ isoforms showed a 
transcriptional increase of ERβ1, that is the active isoform, whereas ERβ2 and ERβ5 
truncated isoforms decreased. p16 increase and cyclin D1 decrease had also been 
confirmed at protein level, by western blot. Finally, the adhesion analysis reported a 
differentiation phenotype characterized by stretched-shaped cells induced by 3l 
treatment.
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This project focuses on the potential role of molecule 3l in depleting cyclin D1 
protein level. 
Cyclin D1 has been recently studied as an important protein in DNA damage repair 
mechanisms, especially in homologous recombination-directed repair (HDR). Cyclin 
D1 is recruited to damaged foci by BRCA2 and it enhances RAD51 binding to BRCA2 
because cyclin D1 prevents BRCA2 inhibitory phosphorylation on serine 3291. 
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Furthermore, cyclin D1 is essential for RAD51 gene upregulation in case of double-
stranded break (DSB). 
3l has been showed to reduce cyclin D1 transcript and protein level at 24 hours of 
treatment of about 60% (Figure 2.2).
72
 
   
   
 
 
 
 
 
 
Figure 2.2: Cyclin D1 protein quantification by western blot 24 hours after 5 µM 3l 
treatment of IGROV1 cells.
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For this reason, 3l treatment could be used to study cyclin D1 role in DNA damage 
repair, especially in an hormone-dependent cancer as ovarian cancer, that has not 
been well addressed yet. 
The experimental model of the project consists of: 
 3l 5 µM treatment for 24 hours to deplete cyclin D1 expression 
 UV irradiation to induce DSB damages. 
In this way, the consequences of induced DSBs could be analyzed in IGROV1 cells: 
formation of the repair complex on damaged sites is the crucial event to prevent 
propagation of the damage. 
First of all, it has been essential to set up time and duration of UV treatment, using the 
well studied breast cancer cell line MCF7 as a template. Then, phosphorylation of 
histone H2AX on serine 139 has been detected and quantified to prove that UV 
irradiation induces DNA damage. RAD51 gene upregulation has been analysed by qRT-
PCR to check whether cyclin D1 is really important for RAD51 expression. By confocal 
microscopy, colocalization of the repair complex BRCA2-cyclin D1-RAD51 has been 
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analysed on the γH2AX foci. Finally, siRNA silencing of CCND1 gene has been 
assessed to confirm the effect on repair pathway caused by 3l-dependent cyclin D1 
depletion. 
The combined treatment of a drug leading to a depletion of cyclin D1 and a DNA 
damage inducer, such as irradiation, could be a potent potential therapy to target 
cancers with an elevated rate of DNA repair pathways, especially in case of chemo- 
and radio-resistant tumours. 
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CHAPTER 3 
MATERIAL AND METHODS 
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3.1 Cell culture 
IGROV1, a human epithelial ovarian cancer cell line, and MCF7, a human breast cancer 
cell line, were used in these experiments. Cells were seeded in flasks or plates (Sarstedt) 
at a density of 20,000 cells/cm
2
 and incubated at 37°C in a 5% CO2 atmosphere. The 
composition of the complete medium is given in Table 3.1. 
Table 3.1: Composition of cell complete medium. 
RPMI 1640 (Lonza) 89% 
Fetal bovine serum (FBS) (EuroClone) 10% 
L-glutamine 200 mM (Sigma-Aldrich) in phosphate buffered saline (PBS) 1% 
 
After two washes with PBS, trypsin 0.115% (Seromed) in a solution of PBS-
ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich) 0.02% was used to split cells; 
it was incubated with cells for 5 minutes at 37°C and neutralized with complete 
medium. Cells were finally counted using a Burker chamber. The composition of PBS is 
described in Table 3.2. 
Table 3.2: Composition of phosphate buffered saline. 
NaCl (Sigma-Aldrich) 8 g/L 
Na2HPO4 (Sigma-Aldrich) 1.15 g/L 
KCl (Sigma-Aldrich) 0.2 g/L 
KH2PO4 (Sigma-Aldrich) 0.2 g/L 
 
3.2 Treatments and siRNA silencing 
3l (Figure 2.1) was dissolved in dimethyl sulfoxide (DMSO) (Sigma-Aldrich) at 20 mM 
concentration and cells were treated at the final concentration of 5 µM for 24 hours. 
UV irradiation was set up: cells were put for 15 minutes under a nominal power 30 W  
UV-C lamp (Philips) at a distance of 55 cm. 
siRNA silencing was applied after 72 hours of adhesion, when cells were 70% 
confluent. The specific siRNA against CCND1 gene and the scramble siRNA used in 
this thesis are described in Table 3.3. 
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Table 3.3: Custom validated siRNA used for the experiments. 
Validated Silencer Select siRNA  (Thermo Fisher Scientific) s229 
Silencer Select Negative Control siRNA (Thermo Fisher Scientific) #1 
 
siRNAs were dissolved in RNase-free water up to a 10 µM stock. A first 1:100 dilution 
siRNA stock was assessed in OptiMEM (Thermo Fisher Scientific). The RNAiMAX 
(Thermo Fisher Scientific) solution was 1:50 diluted in OptiMEM, too. The diluted 
solution of siRNA was added to an equal volume of the diluted RNAiMAX, everything 
was gently resuspended and incubated at room temperature for 20 minutes. Finally, the 
siRNA-RNAiMAX solution was 1:5 diluted in OptiMEM medium and added drop by 
drop to cells. In this manner, the final siRNA treatment optimized concentration was 10 
nM. After 24 hours of siRNA treatment, the medium was changed in complete RPMI 
1640 medium and cells were analyzed 24 hours after medium change. 
Cells were treated like described in Table 3.4. 
Table 3.4: Samples description. 
CTRL Control cells (no treatment nor irradiation) 
UV 
Cells UV-irradiated 72 hours after seeding and analyzed 4 hours after 
irradiation 
3l 
Cells 3l-treated 72 hours after seeding and analyzed 28 hours after 
treatment 
3l/UV 
Cells 3l-treated 72 hours after seeding, UV-irradiated 24 hours after 
treatment and analyzed 4 hours after irradiation 
siRNA 
Cells specific siRNA-treated 72 hours after seeding and analyzed 52 
hours after treatment 
siRNA/UV 
Cells specific siRNA-treated 72 hours after seeding, UV-irradiated 48 
hours after treatment and analyzed 4 hours after irradiation 
scramble 
Cells scramble siRNA-treated 72 hours after seeding and analyzed 52 
hours after treatment 
scramble/UV 
Cells scramble siRNA-treated 72 hours after seeding, UV-irradiated 48 
hours after treatment and analyzed 4 hours after irradiation 
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3.3 RNA extraction 
IGROV1 cells were seeded and treated as described in Paragraph 3.2. Then, cells were 
trypsinized and counted. 5 millions cells were centrifuged for 10 minutes at 250 g and 
washed twice with 1 mL of PBS by centrifugation at 3,000 g for 3 minutes. For the 
RNA extraction, the RNeasy Mini Kit (Qiagen) was used. Pelleted cells were lysed with 
350 µL of RLT buffer prepared by adding 10 µL of β-mercaptoethanol (Sigma-Aldrich) 
to 1 mL of buffer, according to the manufacturer’s protocol. To homogenize the 
solution, a syringe with a 20-gauge needle was employed. After the addition of 350 µL 
of 70% ethanol (Sigma-Aldrich), the solution was transferred into a spin column placed 
in a collection tube and centrifuged for 15 seconds at 8,000 g. After the discard of the 
flow-through, 700 µL of the RW1 buffer were added to the column and centrifuged as 
before. Two washes with 500 µL of the RPE buffer were performed by centrifugation at 
8,000 g for 15 seconds (first wash) and for 2 minutes (second wash). Then, to eliminate 
any carry-over of the buffer, the column was centrifuged for 1 minute at full speed with 
a clean collection tube. Finally, RNA was eluted by adding 30 µL of RNase-free water 
directly on the membrane of the column. The membrane was hydrated for 3 minutes at 
room temperature and then centrifuged at 8,000 g for 1 minute. RNA was quantified by 
NanoDrop spectrophotometer (Thermo Scientific) and integrity checked on a 2% 
agarose gel (Sigma-Aldrich). 
 
3.4 Reverse transcription 
RNA was employed to generate cDNA using the Transcriptor High Fidelity cDNA 
Synthesis Kit (Roche). The samples were firstly prepared in a PCR tube, as described in 
Table 3.5. 
Table 3.5: Reagents for RNA reverse transcription (1). 
RNA 1 µg 
Random examer primers 2 µL 
RNase-free water up to 11.4 µL 
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After 10 minutes pre-incubation at 65°C in a thermal cycler (annealing of the primers), 
at each sample mixture the reagents listed in Table 3.6 were added. 
Table 3.6: Reagents for RNA reverse transcription (2). 
Reaction buffer 5x 4 µL 
RNase inhibitors 0.5 µL 
Deoxynucleotides 2 µL 
Dithiothreitol (DTT) 1 µL 
Reverse transcriptase 1.1 µL 
 
cDNA synthesis was accomplished using the temperature program detailed in Table 3.7. 
Table 3.7: Temperature program for RNA reverse transcription. 
Activation of the enzyme 10 minutes 29°C 
Transcription 60 minutes 48°C 
Inactivation of the enzyme 5 minutes 85°C 
 
3.5 Quantitative Real-Time PCR 
cDNA was used to analyze the levels of transcripts by quantitative Real-Time PCR 
(qRT-PCR). The LightCycler FastStart DNA Master SYBR Green I kit (Roche) and the 
LightCycler 2.0 Instrument (Roche) were employed. qRT-PCR mixture composition is 
reported in Table 3.8. 
Table 3.8: Description of reaction mixture for quantitative Real-Time PCR. 
Master mix (containing Sybr Green I, FastStart Taq DNA 
Polymerase, dNTPs, MgCl2 1 mM) diluted 1:10 
Primer forward (FW) 0.3 µM 
Primer reverse (REV) 0.3 µM 
MgCl2 at the final concentration of 2.7 mM 
2 µL of 1:10 diluted cDNA (nuclease-free water for blank control) 
Nuclease-free water up to 12 µL 
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The first gene analyzed was the house-keeping gene glyceraldehyde 3-phosphate 
dehydrogenase (G3PDH) and its CT values were used as standards in the ΔΔCT method 
of results analysis. cDNA samples from IGROV1 treated/irradiated cells were compared 
to control cells. As blank control, a reaction mixture without the sample was always 
used. Samples were analyzed at least in triplicate and Student's t-test was used to verify 
the significance of results (a p-value less than 0.05 was considered significant). Primers 
(Sigma-Aldrich) employed and qRT-PCR conditions are listed in Table 3.9. 
Table 3.9: List of primers and conditions for quantitative Real-Time PCR. 
PRIMER SEQUENCE Tannealing Tfluorescence AMPLICON 
G3PDH FW atttggtcgtattgggcgcc 
60°C 81°C 150 bp 
G3PDH REV acggtgccatggaatttgcc 
CCND1 FW gccaactggtgtttgaaagta 
60°C 77°C 88 bp 
CCND1 REV tccggtgtgaaacatctaaga 
RAD51 FW cgagcgttcaacacagacca 
60°C 80°C 98 bp 
RAD51 REV gtggcactgtctacaataagca 
 
After the qRT-PCR analysis, the presence of a single amplicon at the expected size was 
verified on a 1.8% agarose gel. 
 
3.6 Total protein extraction 
Cells were seeded and treated as described in Paragraph 3.2. They were then washed 
twice with PBS and incubated with 500 µL of the lysis buffer radio 
immunoprecipitation assay (RIPA) and 500 µL of the buffer HNTG at 4°C for 15 
minutes with agitation. After the cell lysis, the solution was centrifuged for 20 minutes 
at 8,000 g and the supernatant containing the proteins was quantified using the Bio-Rad 
protein assay (Bio-Rad) based on the method of Bradford. The compositions of the 
RIPA lysis buffer and the HNTG buffer are given in Table 3.10. 
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Table 3.10: Compositions of RIPA lysis buffer and HNTG buffer for protein extraction. 
RIPA Buffer 
Trizma Base - HCl, pH 7.4 (Sigma-Aldrich) 50 mM 
NaCl 150 mM 
EDTA 1 mM 
NaF (Sigma-Aldrich) 1 mM 
Sodium deoxycholate (Sigma-Aldrich) 1% 
Triton X-100 (Sigma-Aldrich) 1% 
Sodium dodecyl sulfate (SDS) (Sigma-Aldrich) 0.1% 
Sodium orthovanadate (Sigma-Aldrich) 1 mM 
Leupeptin, aprotinin, antipain, pepstatin A (Calbiochem), 
phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich) 
10 µg/mL 
HNTG Buffer 
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
(HEPES), pH 7.4 (Sigma-Aldrich) 
50 mM 
NaCl 150 mM 
Triton X-100 0.1% 
Glycerol (Sigma-Aldrich) 10% 
 
3.7 Histone proteins isolation 
Cells were seeded and treated as described in Paragraph 3.2. They were trypsinized and 
counted, then centrifuged for 10 minutes at 250 g and washed three times with 1 mL of 
PBS by centrifugation at 3,000 g for 3 minutes at 4°C. To extract histones, 750 µL of 
lysis buffer were added to pelleted cells and the solution was incubated on ice for 15 
minutes. The composition of the lysis buffer for histone extraction is reported in Table 
3.11. 
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Table 3.11: Composition of lysis buffer for histone extraction. 
Buffer Na-PO4, pH 7.4 (Sigma-Aldrich) 0.01 M 
NaCl 10 mM 
MgCl2 (Sigma-Aldrich) 5 mM 
(Octylphenoxy)polyethoxyethanol (NONIDET P-40) (Sigma-Aldrich) 0.1% 
Sodium orthovanadate 0.5 mM 
Leupeptin, aprotinin, antipain, pepstatin A, PMSF 10 µg/mL 
 
After 15 minutes of incubation, 250 µL of paraformaldehyde 3% in PBS (Sigma-
Aldrich) were added to the solution that was incubated on ice for 30 minutes. It was 
then centrifuged at 3,000 g for 3 minutes at 4°C and the pellet was washed twice with 1 
mL of PBS. The pellet was suspended in 200 µL of H2SO4 0.2 M and incubated for 1 
hour at 4°C. Then, the solution was centrifuged for 5 minutes at full speed and the 
supernatant was mixed with 1 mL of acetone and left overnight at -20°C. The following 
day, the solution was centrifuged for 5 minutes at 8,000 g, the pellet composed by 
histones was dried, resuspended in 30 µL of water and quantified using the Bio-Rad 
protein assay (Bio-Rad) based on the method of Bradford. 
 
3.8 Western blot 
Proteins were analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) and western blot on nitrocellulose membrane. To detect cyclin D1 from 
total protein lysate, 30 µg of this were resolved on a 12.5% density gel in running buffer 
at 200 V for 1 hour. 10 µg of isolated histones were detected resolving samples on a 
15% gel in running buffer at 150 V for 90 minutes. The compositions of the running 
buffer is described in Table 3.12.  
Table 3.12: Composition of running buffer for SDS-PAGE. 
Trizma Base 25 mM 
Glycine (Sigma-Aldrich) 192 mM 
SDS 0.1% 
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Western blot was performed in transfer buffer at 100 V for 1 hour. The composition of 
the transfer buffer is given in Table 3.13. 
Table 3.13: Composition of transfer buffer for western blot. 
Trizma Base 25 mM 
Glycine 192 mM 
Methanol (Sigma-Aldrich) 20% 
 
After electrophoresis and western blot, the polyacrylamide gel was visualized by 
Coomassie brilliant blue R-250 (Sigma-Aldrich). The nitrocellulose membrane was 
initially blocked by incubation with PBS-polyoxyethylene sorbitan monolaurate 
(TWEEN 20) 0.1% (Sigma-Aldrich) in agitation for 1 hour, then it was incubated as 
before with specific primary antibody diluted in PBS-TWEEN 20 0.1%. In Table 3.14 
the specific primary antibodies utilized with their related dilutions are listed. 
Table 3.14: Primary antibodies used in western blot and their dilutions. 
Mouse anti-cyclin D1 (Millipore) 1:500 
Rabbit anti-γH2AX (Santa Cruz Biotechnology) 1:500 
Mouse anti-βactin (Sigma-Aldrich) 1:5,000 
 
After five washes with PBS-TWEEN 20 0.1%, the membrane was incubated as before 
with secondary horseradish peroxidase-conjugated antibody (GE Healthcare) diluted 
1:20,000 in PBS-TWEEN 20 0.1%. After more five washes with PBS-TWEEN 20 
0.1%, antibody binding was detected by WESTAR EtaC 2.0 (Cyanagen) and 
quantification was done by Fluor-S Max MultiImager (Bio-Rad) using βactin signal or 
total histone signal as control. Mean of at least three independent analysis and Student's 
t-test were used to verify the significance of results (a p-value less than 0.05 was 
considered significant). 
 
3.9 Immunofluorescence 
IGROV1/MCF7 cells were seeded on glass slides and after 72 hours they were treated, 
as described in Paragraph 3.2. Cells were after washed twice with 1 mL of PBS and 
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fixed with 500 µL of paraformaldehyde 3% for 10 minutes. Glass slides were washed 
twice with 1 mL of PBS-glycine 0.1 M and washed twice again with 1 mL of PBS-
bovine serum albumin (BSA) 1% (Sigma-Aldrich). Cells were permeabilized by 
incubation for 3 minutes at -20°C with some drops of 70% ethanol and washed twice 
with 1 mL of PBS-BSA 1%. At this point, samples were incubated for 1 hour in 
agitation with specific primary antibody diluted in PBS-BSA 1%. The specific primary 
antibodies used and their related dilutions are listed in Table 3.15. 
Table 3.15: Primary antibodies used for immunofluorescence and their dilutions. 
Mouse anti-cyclin D1 (Millipore) 1:250 
Rabbit anti-γH2AX (Santa Cruz Biotechnology) 1:250 
Rabbit anti-RAD51 (Santa Cruz Biotechnology) 1:250 
Rabbit anti-BRCA2 (Santa Cruz Biotechnology) 1:400 
 
Glass slides were washed again twice with 1 mL of PBS-BSA 1% and incubated as 
before with secondary fluorescent antibody 1:1,000 diluted in PBS-BSA 1%: Alexa 
Fluor 568 or fluorescein isothiocyanate (FITC)-conjugated antibodies (Life 
Technologies). Finally, two washes with 1 mL of PBS-BSA 1% were performed and 
cells were incubated with 4',6-diamidino-2-phenylindole (DAPI) 5 µg/mL in PBS for 5 
minutes at 37°C. Samples were mounted in Mowiol solution (Calbiochem), before 
being observed by a fluorescent confocal microscope (Nikon C1s). Quantification was 
managed using Adobe Photoshop CS3 by selecting at least seven cells in three different 
acquisitions for each sample. Student's t-test was used to verify the significance of 
results (a p-value less than 0.05 was considered significant). 
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CHAPTER 4 
RESULTS 
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4.1 Set up of UV exposure and repair time point 
The first experiments focused on the set up of UV exposure and time point for the repair 
analysis: breast cancer MCF7 cells have been taken as a model because they are 
normally used to study homologous recombination-directed repair pathway in literature. 
Different time of exposure were used to irradiate MCF7 cells and analysis was assessed 
at different time points after UV irradiation. The optimal UV irradiation should induce 
DNA damage and repair, but not cell death; the optimal time point for DNA repair 
analysis should immortalize the repair complex BRCA2-cyclin D1-RAD51 on repair 
foci, characterized by the phosphorylation of histone H2AX on serine 139 (γH2AX). 
Later, after the set up, the experiments focused on ovarian cancer, such as IGROV1 
cells, the cellular model of this project. 
At the beginning, different UV exposure (5 minutes, 15 minutes, 30 minutes) were 
analyzed on MCF7 cells: 30 minutes of UV exposure killed nearly all the cells after 24 
hours of treatment; while 5 minutes of UV exposure did not show damaged foci (data 
not showed). For this reason, 15 minutes of UV exposure were decided as the optimal 
exposure for DNA damage induction. 
The quantification of the double-stranded break (DSB) marker γH2AX was analyzed in 
MCF7 cells at different time points after UV irradiation for 15 minutes. Histone 
proteins were isolated and separated by SDS-PAGE; γH2AX was identified by western 
blot and quantified by normalization on the amount of total histones in the same gel lane 
(Figure 4.1). 
The time point analysis showed that UV irradiation for 15 minutes induced an 
hyperphosphorylation of histone H2AX that was present already after 2 hours, that 
increased at 4 hours and doubled at 6 hours after irradiation. Time point of 4 hours after 
irradiation was selected as an optimal time point of analysis. 
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Figure 4.1: Quantification of γH2AX marker in MCF7 cells by western blot. CTRL 
control sample, UV2h-UV6h histones extracted 2-6 hours after UV irradiation for 15 
minutes. 
Then, BRCA2-cyclin D1 complex was identified in MCF7 cells by immunoflurescence 
after 4 hours and 24 hours from UV irradiation (Figure 4.2). 
 
 
Figure 4.2: Immunofluorescence of BRCA2 (green) and cyclin D1 (red) proteins in 
MCF7 cells. UV4h-UV24h cells fixed 4-24 hours after UV irradiation for 15 minutes. 
BRCA2-cyclin D1 complex was present in MCF7 cells nucleus after 4 hours from UV 
irradiation: clear colocalization yellow dots were present in some cells, like the zoomed 
one. 24 hours after UV irradiation the immunofluorescence analysis showed the 
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resolution of damage with no colocalization of cyclin D1 and BRCA2. Here again, time 
point of 4 hours after irradiation was selected as the optimal one. 
 
4.2 Repair proteins colocalization in MCF7 cells 
Once established the UV exposure (15 minutes) and the time point for colocalization 
analysis of repair proteins (4 hours after irradiation), immunofluorescence analysis of 
control MCF7 cells and irradiated cells was performed. In Figure 4.3 γH2AX and 
cyclin D1 immunofluorescences are reported. 
 
 
Figure 4.3: Immunofluorescence of γH2AX (green) and cyclin D1 (red) proteins in 
MCF7 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes. 
The results showed an increase in γH2AX-positive cells when irradiated with UV. 
Furthermore, γH2AX-cyclin D1 colocalization signal was more present in the nucleus 
of these damaged cells, compared to control cells. 
In Figure 4.4 BRCA2 and cyclin D1 immunofluorescences are reported. 
In this images, the decrease of cyclin D1 in UV-irradiated cells compared to control 
MCF7 cells was underlined. Despite this decrease, BRCA2-cyclin D1 colocalization 
was present in damaged cells. 
γH2AX                           cyclin D1                          merge 
CTRL 
 
 
 
 
UV 
48 
 
 
 
Figure 4.4: Immunofluorescence of BRCA2 (red) and cyclin D1 (green) proteins in 
MCF7 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes. 
 
 
Figure 4.5: Immunofluorescence of cyclin D1 (red) and RAD51 (green) proteins in 
MCF7 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes. 
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In Figure 4.5 cyclin D1 and RAD51 are identified by immunofluorescence in control 
MCF7 cells and UV-irradiated cells. 
These results showed an increase in the amount of RAD51 protein in cells irradiated 
with UV and cyclin D1-RAD51 yellow colocalization signal only in damaged cells. 
In Figure 4.6 γH2AX and RAD51 immunofluorescences are reported. 
  
 
Figure 4.6: Immunofluorescence of γH2AX (green) and RAD51 (red) proteins in MCF7 
cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 minutes. 
UV irradiation for 15 minutes induced colocalization of γH2AX and RAD51 in MCF7 
cells. 
 
4.3 Induction of DNA damage in IGROV1 cells 
After the repair mechanisms analysis in MCF7 cells, the research focused on ovarian 
cancer IGROV1 cells. The quantification of the DSB marker γH2AX was analyzed in 
IGROV1 cells at different time points after UV irradiation for 15 minutes. Histone 
proteins were isolated and separated by SDS-PAGE; γH2AX was identified by western 
blot and quantified by normalization on the amount of total histones in the same gel 
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lane. Quantification of three independent analysis was done and Student's t-test was 
used to check the significance of the results (Figure 4.7). 
 
 
 
  
Figure 4.7: Quantification of γH2AX marker in IGROV1 cells by western blot. CTRL 
control sample, UV2h-UV6h histones extracted 2-6 hours after UV irradiation for 15 
minutes. (* p ≤ 0.05 vs CTRL) 
The time point analysis showed that UV irradiation for 15 minutes induced an 
hyperphosphorylation on serine 139 of histone H2AX that was present already after 2 
hours, that persisted at 4 hours and increased 6 hours after irradiation. Given these 
results, time point of 4 hours after irradiation was considered optimal also in IGROV1 
cells. 
After 4 hours from irradiation, γH2AX and RAD51 protein amounts were quantified by 
immunofluorescence (Figure 4.8). At least seven cells in three different acquisitions 
were selected for quantification and Student's t-test was used to verify the significance 
of results. 
UV irradiation caused an increased amount of the marker γH2AX, signal of induced 
DNA damage; the recombinase RAD51 was also increased in response to DSBs. 
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Figure 4.8: Quantification of γH2AX (red) and RAD51 (green) proteins by 
immunofluorescence in IGROV1 cells. CTRL control sample, UV cells fixed 4 hours 
after UV irradiation for 15 minutes. (* p ≤ 0.05, *** p ≤ 0.005 vs CTRL) 
 
4.4 3l treatment inhibits DNA repair complex 
At this point, IGROV1 cells treated with 3l were introduced in the analysis. The 
quantification of γH2AX marker was assessed after 5 µM 3l treatment for 28 hours and 
after 4 hours from UV irradiation of 3l-treated cells. Histone proteins were isolated and 
separated by SDS-PAGE; γH2AX was identified by western blot and quantified by 
normalization on the amount of total histones in the same gel lane. Quantification of 
three independent analysis was done and Student's t-test was used to check the 
significance of the results (Figure 4.9). 
 
0 
10 
20 
30 
40 
50 
60 
γH2AX RAD51 
F
lu
o
re
sc
en
ce
  
CTRL 
UV 
* 
*** 
CTRL                                         UV 
γH2AX   
RAD51         
52 
 
 
 
 
 
Figure 4.9: Quantification of γH2AX marker in IGROV1 cells by western blot. CTRL 
control sample, UV histones extracted 4 hours after UV irradiation for 15 minutes, 3l 
histones extracted 28 hours after 5 µM 3l treatment, 3l/UV histones extracted 28 hours 
after 5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes. (* p ≤ 0.05 vs 
CTRL, # p ≤ 0.05 vs 3l) 
The analysis showed a huge increase of DSBs marker in irradiated cells compared to 
control cells. Furthermore, UV irradiation significantly increased H2AX 
phosphorylation in 3l-treated cells for 28 hours compared to control cells and to 3l-
treated cells. 
In Figure 4.10 and Figure 4.11 BRCA2 and cyclin D1 immunofluorescences in control, 
UV-irradiated and 3l-treated cells are reported and quantified by selecting at least seven 
cells in three different acquisitions for each sample. Student's t-test was used to verify 
the significance of results. 
These results showed that 3l treatment reduced significantly cyclin D1 protein amount 
and that BRCA2-cyclin D1 point colocalization was present only in IGROV1 cells 
irradiated with UV. 
 
 
0 
500 
1000 
1500 
2000 
2500 
3000 
3500 
CTRL UV 3l  3l/UV 
%
 d
en
si
to
m
et
ry
 
*# 
* 
CTRL     UV          3l         3l/UV 
γH2AX 
total H1 
53 
 
 
 
Figure 4.10: Immunofluorescence of BRCA2 (red) and cyclin D1 (green) proteins in 
IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes, 3l cells fixed 28 hours after 5 µM 3l treatment. 
 
Figure 4.11: Quantification of BRCA2 and cyclin D1 proteins by immunofluorescence 
in IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 
15 minutes, 3l cells fixed 28 hours after 5 µM 3l treatment. (** p ≤ 0.01 vs CTRL) 
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Then, qRT-PCR analysis of CCND1 and RAD51 genes was used to study cyclin D1 
protein-dependent RAD51 expression (Figure 4.12). qRT-PCR analysis was managed 
as described in Paragraph 3.5. 
 
Figure 4.12: 2
-ΔΔCT
 values of CCND1 and RAD51 gene expressions in IGROV1 cells. 
CTRL control sample, UV RNA extracted 4 hours after UV irradiation for 15 minutes, 
3l RNA extracted 28 hours after 5 µM 3l treatment, 3l/UV RNA extracted 28 hours after 
5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes. (* p ≤ 0.05, *** p ≤ 
0.005, **** p ≤ 0.001  vs CTRL, # p ≤ 0.05, ### p ≤ 0.005 vs 3l) 
These results underlined the down-regulation of CCND1 both in UV-irradiated and 3l-
treated cells. 3l/UV sample presented a decrease in cyclin D1 expression compared to 
control. Analysis of RAD51 mRNA showed its up-regulation induced by irradiation, 
that was not present in cells treated with 3l and then irradiated. 
Subsequently, cyclin D1 and RAD51 immunofluorescences in control, UV-irradiated, 
3l-treated and irradiated cells after 3l treatment were analyzed and quantified (Figure 
4.13 and Figure 4.14). At least seven cells in three different acquisitions for each 
sample were selected and Student's t-test was used to verify the significance of results. 
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Figure 4.13: Immunofluorescence of cyclin D1 (red) and RAD51 (green) proteins in 
IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes, 3l cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours after 
5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes. 
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Figure 4.14: Quantification of cyclin D1 and RAD51 proteins by immunofluorescence 
in IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 
15 minutes, 3l cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours 
after 5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes. (* p ≤ 0.05, ** 
p ≤ 0.01, *** p ≤ 0.005, **** p ≤ 0.001  vs CTRL, # p ≤ 0.05, #### p ≤ 0.001 vs 3l) 
Here, only in UV sample cyclin D1-RAD51 colocalization was present. Furthermore, 
the cyclin D1 amount decreased in all the treated cells, and RAD51 increased in UV-
irradiated and 3l-treated cells, but not in cells treated with 3l for 24 hours and then 
irradiated. 
 
4.5 Set up of CCND1 siRNA silencing 
siRNA silencing of CCND1 gene codifying cyclin D1 protein was set up to have a 
comparable sample for 3l treatment. Custom and validated siRNAs were used for the 
analysis: a specific anti-CCND1 and a correspondent negative siRNA were chosen. 
First, the silencing concentration was set up by quantification of cyclin D1 protein 48 
hours after treatment with the siRNA. Total protein lysates were resolved in SDS-PAGE 
and cyclin D1 protein was identified by specific antibody in western blot. By 
normalization on the amount of βactin, quantification of cyclin D1 in the specific anti-
CCND1 siRNA sample was compared with the relative negative sample (Figure 4.15). 
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Figure 4.15: Quantification of cyclin D1 in IGROV1 cells by western blot. CTRL 
control sample, siRNA 10nM-20nM proteins extracted 48 hours after treatment with 
anti-CCND1 siRNA 10 nM-20 nM, scramble 10nM-20nM proteins extracted 48 hours 
after treatment with scramble siRNA 10 nM-20 nM. 
The results showed a nearly total silencing with both concentrations: 10 nM siRNA was 
chosen as the optimal concentration for further analysis. 
Secondly, a silencing time course was assessed by quantification of cyclin D1 protein 
48-72-96 hours after treatment with siRNA 10 nM. Total protein lysates were resolved 
in SDS-PAGE and cyclin D1 protein was identified by specific antibody in western 
blot. By normalization on the amount of βactin, quantification of cyclin D1 in the 
specific siRNA sample was compared with the relative scramble sample (Figure 4.16). 
These results showed the best silencing after 48 hours and this time point was chosen as 
optimal. 
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Figure 4.16: Quantification of cyclin D1 in IGROV1 cells by western blot. CTRL 
control sample, siRNA 48h-96h proteins extracted 48-96 hours after treatment with 
anti-CCND1 siRNA 10 nM, scramble 48h-96h proteins extracted 48-96 hours after 
treatment with scramble siRNA 10 nM. 
 
4.6 Comparison between 3l treatment and CCND1 silencing 
4.6.1 γH2AX and cyclin D1 quantification 
In the last part of the project, IGROV1 cells silenced for CCND1 were introduced in the 
samples list to compare them with cells treated with 3l. The γH2AX marker was again 
analyzed: histones were isolated and separated by SDS-PAGE, γH2AX was identified 
by western blot and quantified by normalization on the amount of total histones in the 
same gel lane. Quantification of three independent analyses was done and Student's t-
test was used to check the significance of the results (Figure 4.17). 
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Figure 4.17: Quantification of γH2AX marker in IGROV1 cells by western blot. CTRL 
control sample, UV histones extracted 4 hours after UV irradiation for 15 minutes, 3l 
histones extracted 28 hours after 5 µM 3l treatment, 3l/UV histones extracted 28 hours 
after 5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA histones 
extracted 52 hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV histones 
extracted 52 hours after treatment with anti-CCND1 siRNA 10 nM and 4 hours after 
UV irradiation for 15 minutes. (* p ≤ 0.05, *** p ≤ 0.005 vs CTRL, # p ≤ 0.05 vs 3l, + p 
≤ 0.05 vs siRNA) 
The quantification analysis presented a hyperphosphorylation of histone H2AX twenty-
fold higher in all samples irradiated with UV for 15 minutes, indicating induced DNA 
damage. 
In Figure 4.18 cyclin D1 protein was then quantified by western blot in all the samples. 
Results showed a decrease in cyclin D1 amount in all the cells irradiated with UV, even 
if this decrease was evident also in cells treated only with 3l as well as cells treated only 
with selected siRNA against CCND1. 
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Figure 4.18: Quantification of cyclin D1 in IGROV1 cells by western blot. CTRL 
control sample, UV proteins extracted 4 hours after UV irradiation for 15 minutes, 3l 
proteins extracted 28 hours after 5 µM 3l treatment, 3l/UV proteins extracted 28 hours 
after 5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA proteins 
extracted 52 hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV proteins 
extracted 52 hours after treatment with anti-CCND1 siRNA 10 nM and 4 hours after 
UV irradiation for 15 minutes. (* p ≤ 0.05, *** p ≤ 0.005, **** p ≤ 0.001 vs CTRL, 
#### p ≤ 0.05 vs 3l) 
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4.6.2 CCND1 and RAD51 genes expression 
qRT-PCR analysis of CCND1 (Figure 4.19) and RAD51 (Figure 4.20) genes was 
applied to study cyclin D1 protein-dependent RAD51 expression in all the samples set. 
qRT-PCR analysis was performed as described in Paragraph 3.5. 
 
Figure 4.19: 2
-ΔΔCT
 values of CCND1 gene expression in IGROV1 cells. CTRL control 
sample, UV RNA extracted 4 hours after UV irradiation for 15 minutes, 3l RNA 
extracted 28 hours after 5 µM 3l treatment, 3l/UV RNA extracted 28 hours after 5 µM 
3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA RNA extracted 52 
hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV RNA extracted 52 
hours after treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation 
for 15 minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 
10 nM, scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 
nM and 4 hours after UV irradiation for 15 minutes. (*** p ≤ 0.005, **** p ≤ 0.001  vs 
CTRL, ### p ≤ 0.005 vs 3l, @@@ p ≤ 0.005 vs scramble) 
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Figure 4.20: 2
-ΔΔCT
 values of RAD51 gene expression in IGROV1 cells. CTRL control 
sample, UV RNA extracted 4 hours after UV irradiation for 15 minutes, 3l RNA 
extracted 28 hours after 5 µM 3l treatment, 3l/UV RNA extracted 28 hours after 5 µM 
3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA RNA extracted 52 
hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV RNA extracted 52 
hours after treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation 
for 15 minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 
10 nM, scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 
nM and 4 hours after UV irradiation for 15 minutes. (* p ≤ 0.05, *** p ≤ 0.005  vs 
CTRL) 
Irradiation induced down-regulation of CCND1 and up-regulation of RAD51 genes. 
Surprisingly, 3l-treated and silenced cells presented CCND1 down-regulation but not 
present RAD51 up-regulation in response to UV irradiation. Scramble sample behaved 
like control cells. 
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4.6.3 Immunofluorescence of repair proteins 
Last experiments' scope was to detect the repair complex by immunofluorescence. The 
first analysis was the detection (Figure 4.21) and the quantification (Figure 4.22) of 
marker γH2AX. At least seven cells in three different acquisitions for each sample were 
selected and Student's t-test was used to verify the significance of the results. 
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Figure 4.21: Immunofluorescence of γH2AX (red) protein in IGROV1 cells. DAPI 
(blue). CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes, 3l cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours after 
5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA cells fixed 52 
hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV cells fixed 52 hours 
after treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation for 15 
minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 10 nM, 
scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 nM and 4 
hours after UV irradiation for 15 minutes. 
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Figure 4.22: Quantification of γH2AX protein by immunofluorescence in IGROV1 cells. 
CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 minutes, 3l 
cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours after 5 µM 3l 
treatment and 4 hours after UV irradiation for 15 minutes, siRNA cells fixed 52 hours 
after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV cells fixed 52 hours after 
treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation for 15 
minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 10 nM, 
scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 nM and 4 
hours after UV irradiation for 15 minutes. (* p ≤ 0.05, *** p ≤ 0.005, **** p ≤ 0.001  
vs CTRL, #### p ≤ 0.001 vs 3l, ++++ p ≤ 0.001 vs siRNA, @@@@ p ≤ 0.001 vs 
scramble ) 
These results showed the increase in hyperphosphorylation of histone H2AX in all the 
samples irradiated with UV rays. 
The second analysis was the detection (Figure 4.23) and the quantification (Figure 
4.24) of BRCA2 and cyclin D1 proteins by immunofluorescence. At least seven cells in 
three different acquisitions for each sample were selected and Student's t-test was used 
to verify the significance of the results. 
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Figure 4.23: Immunofluorescence of BRCA2 (green) and cyclin D1 (red) proteins in 
IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes, 3l cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours after 
5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA cells fixed 52 
hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV cells fixed 52 hours 
after treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation for 15 
minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 10 nM, 
scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 nM and 4 
hours after UV irradiation for 15 minutes. 
siRNA/UV 
 
 
 
 
scramble 
 
 
 
 
scramble/UV 
68 
 
 
Figure 4.24: Quantification of BRCA2 and cyclin D1 proteins by immunofluorescence 
in IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 
15 minutes, 3l cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours 
after 5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA cells 
fixed 52 hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV cells fixed 52 
hours after treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation 
for 15 minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 
10 nM, scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 
nM and 4 hours after UV irradiation for 15 minutes. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.005, **** p ≤ 0.001  vs CTRL, # p ≤ 0.05, ### p ≤ 0.005 vs 3l, ++++ p ≤ 0.001 vs 
siRNA, @ p ≤ 0.05, @@@@ p ≤ 0.001 vs scramble) 
UV irradiation induced BRCA2-cyclin D1 colocalization, but only in CTRL and 
scramble samples. 3l treatment and siRNA silencing induced same effects in IGROV1 
cells: down-regulation of both BRCA2 and cyclin D1. 
Detection (Figure 4.25) and quantification (Figure 4.26) of BRCA2 and RAD51 by 
immunofluorescence were the next steps. At least seven cells in three different 
acquisitions for each sample were selected and Student's t-test was used to verify the 
significance of the results. 
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Figure 4.25: Immunofluorescence of BRCA2 (green) and RAD51 (red) proteins in 
IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes, 3l cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours after 
5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA cells fixed 52 
hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV cells fixed 52 hours 
after treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation for 15 
minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 10 nM, 
scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 nM and 4 
hours after UV irradiation for 15 minutes. 
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Figure 4.26: Quantification of BRCA2 and RAD51 proteins by immunofluorescence in 
IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes, 3l cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours after 
5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA cells fixed 52 
hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV cells fixed 52 hours 
after treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation for 15 
minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 10 nM, 
scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 nM and 4 
hours after UV irradiation for 15 minutes. (* p ≤ 0.05, **** p ≤ 0.001  vs CTRL, + p ≤ 
0.05, ++ p ≤ 0.01 vs siRNA) 
These results showed no important differences between the samples: BRCA2 
colocalized with RAD51 and only IGROV1 cells treated with 3l presented a significant 
decrease in the amount of recombinase RAD51. 
Finally, detection (Figure 4.27) and the quantification (Figure 4.28) of cyclin D1 and 
RAD51 were carried on. At least seven cells in three different acquisitions for each 
sample were selected and Student's t-test was used to verify the significance of the 
results. 
 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
BRCA2 RAD51 
F
lu
o
re
sc
en
ce
 
CTRL UV 3l 3l/UV 
siRNA siRNA/UV scramble scramble/UV 
* **** 
* 
* 
++ 
+ 
72 
 
 
 
 
 
cyclin D1                        RAD51                           merge          
CTRL 
 
 
 
 
UV 
 
 
 
 
3l 
 
 
 
 
3l/UV 
 
 
 
 
 
 
 
siRNA 
73 
 
 
Figure 4.27: Immunofluorescence of cyclin D1 (red) and RAD51 (green) proteins in 
IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 15 
minutes, 3l cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours after 
5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA cells fixed 52 
hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV cells fixed 52 hours 
after treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation for 15 
minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 10 nM, 
scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 nM and 4 
hours after UV irradiation for 15 minutes. 
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Figure 4.28: Quantification of cyclin D1 and RAD51 proteins by immunofluorescence 
in IGROV1 cells. CTRL control sample, UV cells fixed 4 hours after UV irradiation for 
15 minutes, 3l cells fixed 28 hours after 5 µM 3l treatment, 3l/UV cells fixed 28 hours 
after 5 µM 3l treatment and 4 hours after UV irradiation for 15 minutes, siRNA cells 
fixed 52 hours after treatment with anti-CCND1 siRNA 10 nM, siRNA/UV cells fixed 52 
hours after treatment with anti-CCND1 siRNA 10 nM and 4 hours after UV irradiation 
for 15 minutes, scramble RNA extracted 52 hours after treatment with scramble siRNA 
10 nM, scramble/UV RNA extracted 52 hours after treatment with scramble siRNA 10 
nM and 4 hours after UV irradiation for 15 minutes. (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.005, **** p ≤ 0.001  vs CTRL, ### p ≤ 0.005, #### p ≤ 0.001 vs 3l, + p ≤ 0.05, ++++ 
p ≤ 0.001 vs siRNA, @@@ p ≤ 0.005, @@@@ p ≤ 0.001 vs scramble) 
Remarkably, only IGROV1 cells treated with 3l and cells treated with selected anti-
CCND1 siRNA presented down-regulation of cyclin D1 amount and RAD51 
recombinase. Cyclin D1-RAD51 colocalization was present only in control cells and 
cells treated with scramble siRNA, later irradiated with UV. 
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
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Scope of this thesis was to find a new possible approach for the treatment of ovarian 
cancer: using the human ovarian cancer cell line IGROV1 as a model, this study set up a 
combined treatment to increase sensitivity of these cells to irradiation. This project 
focused on the potential role of molecule 3l, an E-3-(2-chloro-3-indolylmethylene)1,3-
dihydroindol-2one, in depleting cyclin D1 protein level. Cyclin D1 has been recently 
studied as an important protein in DNA damage repair mechanisms, especially in 
homologous recombination-directed repair (HDR). Cyclin D1 is recruited to damaged 
foci by BRCA2 and it enhances RAD51 binding to BRCA2. Furthermore, cyclin D1 is 
essential for RAD51 gene up-regulation in case of double-stranded break (DSB). 3l has 
been showed to reduce cyclin D1 transcript and protein levels and, for this reason, 3l 
treatment was used to study cyclin D1 role in DNA damage repair, especially in an 
hormone-dependent cancer as ovarian cancer, that has not been well addressed yet. 
The experimental model consisted in a first 5 µM 3l treatment for 24 hours in order to 
deplete cyclin D1 expression, with a further UV irradiation to induce DSB damages. In 
this case, the repair of induced DSBs were analyzed in IGROV1 cells with a small 
amount of cyclin D1 protein. 
First of all, time and duration of UV treatment were set up using the well studied breast 
cancer cell line MCF7 as a template: 15 minutes of UV irradiation resulted optimal to 
induce DNA damage, but not cell death; the time point of 4 hours after irradiation 
resulted optimal for DNA repair pathway analysis. In MCF7 cells UV irradiation 
induced DNA damage as histone H2AX was hyperphosphorylated on serine 139 
(γH2AX). Down-regulation of cyclin D1 was present, but the remaining pool of this 
protein was in the nucleus forming BRCA2-cyclin D1-RAD51 repair complex at 
damaged foci. 
Then, UV irradiation set up was confirmed also in IGROV1 cells. CCND1 siRNA 
silencing were also assessed: 10 nM siRNA treatment for 48 hours resulted as the 
maximum silencing pick of cyclin D1 protein. 
In IGROV1 cells, UV irradiation induced H2AX hyperphosphorylation, marker of 
DSBs, in all the samples and a down-regulation of cyclin D1 was also present. UV-
irradiated cells resulted in an up-regulation of RAD51 gene and formation of repair 
complex BRCA2-cyclin D1-RAD51 on damaged foci. 3l-treated cells presented a 
77 
 
depletion of cyclin D1 protein levels and irradiation of these 3l-treated cells induced 
DNA damage as normal. However, 3l-treated and then UV-irradiated cells did not 
present up-regulation of RAD51 gene and they did not present repair proteins 
colocalization. Anti-CCND1 siRNA silenced cells showed comparable results to 3l-
treated cells, while scramble siRNA silenced cells presented comparable results to 
control cells. 
This thesis confirmed the important role of protein cyclin D1 in the repair pathway 
of DSBs: 
 cyclin D1 participates in and it is essential for repair complex formation on 
damaged foci 
 cyclin D1 is necessary for RAD51 gene up-regulation in case of DSB. 
The combined treatment of a drug leading to a depletion of cyclin D1 and a DNA 
damage inducer, such as irradiation, could be a potent potential therapy to target 
cancers with an elevated rate of DNA repair pathways, especially in case of chemo- 
and radio-resistant tumours. 
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